EUVIMEDEUVIMED entdecken
Open Access

Post-Transplant Cyclophosphamide–Based Graft-Versus-Host Disease Prophylaxis Attenuates Disparity in Outcomes Between Use of Matched or Mismatched Unrelated Donors

Brian C Shaffer iD, Mahasweta Gooptu, Todd E DeFor, Martin Maiers iD, Javier Bolaños-Meade, Ramzi Abboud iD, Adrienne D Briggs, Farhad Khimani iD, Dipenkumar Modi iD, Richard Newcomb iD, Elizabeth J Shpall, Caitrin Bupp iD und 7 weitere

Journal of Clinical Oncology · 2024-10 · 42 (28) · 3277-3286

DOI: 10.1200/jco.24.00184 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Clinical Oncology, 2024-10. Verfasst von Brian C Shaffer und 18 weiteren Autor:innen. Beteiligte Einrichtung: Adult Bone Marrow Transplantation Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY. Hauptthemen laut MEDLINE: Cyclophosphamide, Hematopoietic Stem Cell Transplantation, Graft vs Host Disease, Unrelated Donors. Die Arbeit wurde bisher 117-mal zitiert (Crossref) und nennt 33 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NCI NIH HHS, NHLBI NIH HHS, NIAID NIH HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

PURPOSE Access to allogeneic hematopoietic cell transplantation (HCT) remains limited among persons of non-European ancestry if human leukocyte antigen (HLA) matching is required. We evaluated whether post-transplant cyclophosphamide (PTCy)–based graft-versus-host disease (GVHD) prophylaxis improved HCT outcomes with HLA-matched unrelated donor (MUD) and mismatched unrelated donor (MMUD) HCT when compared with calcineurin inhibitor (CNI)–based prophylaxis. METHODS Three-year overall survival (OS) and GVHD-free, relapse-free survival (GRFS) were compared between adult recipients undergoing initial MUD or single HLA locus MMUD HCT with either PTCy- or CNI-based prophylaxis who were reported to the Center for International Blood and Marrow Transplant Research between 2017 and 2021. RESULTS Included were 10,025 HCT recipients (7,272 recipients of MUD with CNI, 1,681 MUD with PTCy, 613 MMUD with CNI, and 459 MMUD with PTCy) who underwent HCT for acute leukemia (70.9%) or myelodysplastic syndromes (29.2%). Median patient age was 60.7 years (range, 18.0-82.7) and median follow-up was 36.6 (range, 3.0-77.8) months. When compared with MUD HCT with PTCy, MMUD HCT with PTCy had similar OS (hazard ratio [HR], 0.96 [95% CI, 0.823 to 1.11]; P = .60) and GRFS (HR, 0.90 [0.79 to 1.02]; P = .1). When compared with MUD HCT with CNI, OS was improved after MUD HCT with PTCy (HR, 0.88 [0.80 to 0.96]; P = .004) and GRFS was improved with PTCy after either MUD (HR, 0.61 [0.57 to 0.66]; P < .0001) or MMUD (HR, 0.68 [0.60 to 0.76]; P < .0001) HCT. Benefit from PTCy was independent of patient ancestry. Global registry level analysis demonstrated that inclusion of MMUD increased donor availability regardless of recipient ancestry. CONCLUSION Use of PTCy results in comparable OS and GRFS using either MUD or MMUD HCT, expanding access to HCT for patients from all racial and ethnic ancestry groups.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

CyclophosphamideHematopoietic Stem Cell TransplantationGraft vs Host DiseaseUnrelated DonorsHumansMiddle AgedFemaleMaleAdultAgedYoung AdultAdolescentCalcineurin InhibitorsImmunosuppressive Agents

Substanzen

CyclophosphamideCalcineurin InhibitorsImmunosuppressive Agents

Autor:innen und Institutionen

  • Adult Bone Marrow Transplantation Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY.
  • Department of Hematology/Oncology, Dana-Farber Cancer Institute, Boston, MA.
  • CIBMTR (Center for International Blood and Marrow Transplant Research), NMDP, Minneapolis, MN.
  • The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, MD.
  • Washington University School of Medicine, St Louis, MO.
  • Cancer Transplant Institute at HonorHealth, Scottsdale, AZ.

ORCID-Profile: Brian C Shaffer, Martin Maiers, Ramzi Abboud, Farhad Khimani, Dipenkumar Modi, Richard Newcomb, Caitrin Bupp, Bronwen E Shaw, Jeffery J Auletta, Steven M Devine, Antonio M Jimenez Jimenez, Monzr M Al Malki

Förderung

  • NCI NIH HHS
  • NHLBI NIH HHS
  • NIAID NIH HHS

Zitieren

APA

Shaffer, B. C., Gooptu, M., DeFor, T. E., Maiers, M., Bolaños-Meade, J., Abboud, R., Briggs, A. D., Khimani, F., Modi, D., Newcomb, R., Shpall, E. J., Bupp, C., Spellman, S. R., Stefanski, H. E., Shaw, B. E., Auletta, J. J., Devine, S. M., Jimenez Jimenez, A. M., & Al Malki, M. M. (2024). Post-Transplant Cyclophosphamide–Based Graft-Versus-Host Disease Prophylaxis Attenuates Disparity in Outcomes Between Use of Matched or Mismatched Unrelated Donors. Journal of Clinical Oncology, 42(28), 3277-3286. https://doi.org/10.1200/jco.24.00184

Vancouver

Shaffer BC, Gooptu M, DeFor TE, Maiers M, Bolaños-Meade J, Abboud R, et al. Post-Transplant Cyclophosphamide–Based Graft-Versus-Host Disease Prophylaxis Attenuates Disparity in Outcomes Between Use of Matched or Mismatched Unrelated Donors. Journal of Clinical Oncology. 2024;42(28):3277-3286. doi:10.1200/jco.24.00184

BibTeX
@article{Shaffer2024,
  author = {Shaffer, Brian C and Gooptu, Mahasweta and DeFor, Todd E and Maiers, Martin and Bolaños-Meade, Javier and Abboud, Ramzi and Briggs, Adrienne D and Khimani, Farhad and Modi, Dipenkumar and Newcomb, Richard and Shpall, Elizabeth J and Bupp, Caitrin and Spellman, Stephen R and Stefanski, Heather E and Shaw, Bronwen E and Auletta, Jeffery J and Devine, Steven M and Jimenez Jimenez, Antonio M and Al Malki, Monzr M},
  title = {Post-Transplant Cyclophosphamide–Based Graft-Versus-Host Disease Prophylaxis Attenuates Disparity in Outcomes Between Use of Matched or Mismatched Unrelated Donors},
  journal = {Journal of Clinical Oncology},
  year = {2024},
  volume = {42},
  number = {28},
  pages = {3277--3286},
  doi = {10.1200/jco.24.00184}
}
Kostenlos starten →